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Abstract 
 
Overdiagnosis, and thus overtreatment, are inevitable 
consequences of most screening programmes; identification of ways 
of minimising the impact of overdiagnosis demands new prospective 
research, in particular the need to separate clinically relevant 
lesions that require active treatment from those that can be safely 
left alone or monitored and only need treated if they change 
characteristics. Breast cancer screening has led to a large increase 
in ductal carcinoma in situ (DCIS) diagnoses. This is a widely 
heterogeneous disease and most DCIS detected through screening 
is of high cytonuclear grade and therefore likely to be important 
clinically. However, the historic practice of surgical treatment for all 
DCIS is unlikely to be optimal for lower risk patients. A clearer 
understanding of how to manage DCIS is required. This article 
describes the background and development of ‘The low risk’ DCIS 
trial (LORIS), a Phase III Trial of Surgery versus Active monitoring.  
LORIS will determine if it is appropriate to manage women with 
screen detected or asymptomatic, low grade, and intermediate 
grade DCIS with low grade features, by active monitoring rather 
than by surgical treatment.  
 
BACKGROUND 
A series of contradictory academic publications and protracted 
debate concerning the estimated benefits and harms of breast 
screening has attracted significant attention in the scientific and 
general press.  An independent UK panel reviewed the evidence for 
harms and benefits of breast screening. The review team concluded 
that breast cancer screening does indeed save lives. However, from 
the available data, the team estimated that for each life saved by 
breast screening 3 women are overdiagnosed [1]. While limitations 
of the review and caveats to the interpretation and reliability of this 
headline metric are clearly stated, this review has provided many 
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with reassurance that breast screening has an important role to 
play in reducing breast cancer mortality with an acceptable 
downside in terms of overtreatment. The Swiss medical board by 
contrast reviewing the same information reached the conclusion 
that there is ‘no clear evidence of any survival benefit’ but ‘clear 
evidence of overtreatment with up to 14 patients getting an 
unnecessary diagnosis for one who possibly benefits’ [2]. On this 
basis the board has recommended winding down the Swiss breast 
screening programme. These divergent interpretations are of course 
not new [3, 4]. Consensus regarding how existing trial data should 
be interpreted seems as far away as ever. The contemporary 
relevance of data from screening trials conducted up to 30 years 
ago is also hard to define. Modern imaging and diagnostics result in 
more lesions being identified, investigated, and treated than was 
the case in the era of the original screening trials. The magnitude of 
current overtreatment as a result of breast screening remains 
difficult to define accurately, leaving women of screening age and 
their doctors with a dilemma about the wisest course of action. 
Clinicians generally continue to recommend surgery in the absence 
of any available evidence-based strategy or access to an 
appropriate clinical trial. The UK screening review recommended 
research into the need for surgery for low grade ductal carcinoma in 
situ (DCIS), an approach regarded by the authors as appropriate to 
attempt to address overtreatment and avoiding the nihilism implied 
by discontinuation of screening altogether. A clinical trial is long 
overdue. 
 
One striking and measurable consequence of breast screening has 
been a substantial rise in women diagnosed with DCIS. In the UK, 
the age standardised incidence of DCIS has risen from 3.6/100,000 
in 1988 to 16.2/100,000 [5], accounting for 20% of screen detected 
neoplastic lesions [6]. If all DCIS is destined to progress to invasive 
disease then it would be reasonable to assume that the treatment 
of screen detected DCIS would result in a reduction in the 
development of invasive breast cancer. However in the same 
period, i.e. 1988 to 2010, invasive breast cancer has risen from 
90.9/100,000 in to 126.2/100,000. [7] These data may be 
explained in part by improved detection techniques (including digital 
mammography and increased use of MRI), as well as by a true 
increase in invasive disease, due to epidemiological factors, but the 
natural history of “pure” DCIS (that occurring in the absence of any 
invasive cancer) remains poorly understood. 
  
 
Accepted criteria for the adoption of a screening test are that the 
natural history of the condition is understood and that treatment 
should be more effective if started early. It has long been assumed 
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that early detection of DCIS and its immediate treatment will also 
result in health benefit, although there is no direct evidence for this. 
The trials demonstrating that adjuvant treatments do reduce 
recurrence of DCIS as further in situ or as invasive carcinoma have 
at the same time been unable to show an impact on mortality. DCIS 
is a heterogeneous disease with variable malignant potential and 
whilst there is no question that some DCIS will progress to invasive 
disease and indeed that high grade DCIS may harbour occult high 
grade invasive cancer [8], it is not fully understood which patients 
require urgent intervention and who can be safely left untreated. 
The Marmot Review recommends that overtreatment be addressed 
by research [1]. At present DCIS is, somewhat crudely, segregated 
by grade. It is clear that high grade DCIS is associated with the 
development of high grade invasive carcinoma, is biologically more 
aggressive and that this is the grade most commonly detected by 
screening. Low and intermediate grade DCIS however account for 
approximately 30% of screen detected lesions and the certainty of 
progression to invasion is less clear. The remainder of this article 
describes the development of the Low Risk DCIS Trial (LORIS), a 
prospective phase III trial of women with asymptomatic or screen 
detected low or low/intermediate grade DCIS randomised to 
immediate surgery and standard adjuvant treatment or to a non-
interventional approach of active monitoring.  
 
The Sloane Project is a UK wide, prospective audit of screen 
detected non-invasive cancer and atypical hyperplasia of the breast.  
It is a multi-disciplinary project involving radiologists, pathologists, 
surgeons and oncologists.  
 
The concentrated expertise of the Sloane Project steering group 
formed the core of the LORIS trial development group. From the 
outset, patient representatives from Independent Cancer Patients' 
Voice (ICPV) were included in this group. ICPV is a patient advocate 
group, independent of established UK cancer charities. Members of 
ICPV embraced the trial idea with enthusiasm and in many ways 
drove the protocol forward, steering it down a route acceptable to 
patients and clinicians alike. It was necessary for the trial protocol 
to address several specific areas and the key ones are considered 
individually below. 
 
 
ELIGIBILITY 
 
AGE 
There was agreement that the patients should be of screening age, 
from first invitation (between age 46 and 49) and that an upper age 
limit was not required. Women are not invited for screening in the 
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UK after the age of 70 but may continue to attend on a three yearly 
basis by request. 
 
 
GRADE 
This eligibility criterion is based both on the results of the UK DCIS 
1 Trial [9] which, from central review, showed comparable local 
recurrence with low and intermediate cytonuclear grade DCIS 
(hazard ratios (HR) of 0.51 and 0.41 respectively compared to high 
grade disease) and the proven inconsistency of reporting at the 
boundary of low and intermediate grades. If future pathological 
classification changes to describe high grade and non-high grade 
DCIS, based on more robust reproducible criteria rather than the 
currently more subjective low, intermediate and high grades, then 
the role of active monitoring in the entire non-high grade group 
could be considered. Wide discussion has provided consensus that 
inclusion in a trial with the randomization to active monitoring DCIS 
should be restricted to low grade disease, and intermediate grade 
with low grade features. 
 
In order to address the recognized issue of reproducibility of 
cytonuclear grading of DCIS, real time central pathology review by 
expert DCIS pathologists using a bespoke web based system for 
slide review strives to ensure that high grade disease is excluded 
and that only patients with low grade, or intermediate grade with 
low grade features, are randomized into this trial. The central 
pathology review provides internal consistency for meeting 
pathological entry criteria across all trial sites. 
 
Until recently, the diagnosis of DCIS was made using small volume 
biopsies, i.e. 14 gauge (G), however large volume vacuum-assisted 
core biopsies (VACB) (e.g. 11G and 8G) are now considered the 
gold standard and are in widespread use in the UK. VACB provides a 
larger tissue sample and improves both the accuracy of 
classification of grade of DCIS and greater assurance of the absence 
of invasion [10, 11]. 
 
SIZE 
DCIS size eligibility criteria were a contentious issue during the 
protocol design. It was discussed at every opportunity during 
development with the wider breast cancer community. There were 
vociferous supporters of only small lesions being eligible and equal 
support for those who thought only patients requiring a mastectomy 
should be able to take part. The protocol writing group found no 
evidence that size should be an eligibility criterion. Individual 
clinicians may choose to only discuss the trial with patients who 
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have DCIS of a size that they are comfortable with randomizing, but 
a prospective randomized trial is the only way to address this issue.  
 
There is no published trial of active monitoring of patients with low 
and low/intermediate grade DCIS of any size diagnosed with VACBs, 
subject to central pathology review and with no mass lesion 
clinically or on imaging. The lack of clear evidence of the benefit of 
surgery for this group of patients provides a strong rationale for 
offering the trial as an alternative approach for this condition.  
 
BIOPSY METHOD 
The trial pathology experts were united in their opinion that VACBs 
were required to determine eligibility and that small volume cores 
alone did not suffice and would not be sufficiently representative. 
Patients who proceed from small volume biopsies to VACBs have all 
diagnostic material reviewed. 
 
IMAGING CRITERIA 
Because the presence of a mass lesion on imaging is associated 
with of a higher chance of an invasive component at excision, those 
patients with any mass lesion present on radiological imaging or 
clinical examination were determined to be ineligible. The 
radiologists concluded, however, that breast ultrasound was not 
essential as a trial procedure but if performed as part of the 
standard diagnostic work up and a mass lesion was seen the patient 
was not eligible for trial entry; thus patients are only eligible if they 
have screen detected or asymptomatic microcalcification with no 
evidence of a mass lesion. 
 
SURGERY ARM 
There was agreement that the surgery arm patients should receive 
the same treatment they would receive were they not in a trial, i.e. 
standard surgical and adjuvant treatment according to local protocol. 
There is great variation in local protocols both for definition of 
completeness of excision (i.e. regarding margin width of uninvolved 
tissue required), and application of adjuvant treatments for DCIS in 
the UK and standardisation of adjuvant treatment would not be 
practical.[6]  
 
ACTIVE MONITORING ARM 
The protocol writing group was in agreement that in the active 
monitoring arm there should be no anti-oestrogen treatment 
because the question the trial addresses is that of overtreatment 
not undertreatment. There is no evidence to suggest how long 
patients treated by endocrine treatment alone should stay on 
therapy. To accommodate divergent opinion the trial will stratify for 
intended endocrine treatment. 
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Annual mammography was widely agreed to be an acceptable 
monitoring method, at least in the medium term. In the long term, 
however, follow up with alternative imaging modalities may 
supersede mammography. There was no enthusiasm for magnetic 
resonance imaging (MRI) to be part of the protocol at present, as 
there was a paucity of evidence for this and substantial evidence 
that it would lead to a higher unnecessary mastectomy rate.  
 
FOLLOW UP IN BOTH ARMS 
There is no data on the long-term outcome of patients receiving no 
treatment for VACB-detected low risk DCIS that has been subject to 
central pathology review. There are a few published series of 
patients in whom the initial pathological diagnosis was missed but 
on retrospective slide review were identified as having previously 
unrecognised DCIS. These patients therefore received no treatment. 
These women had a symptomatic presentation and did not have a 
VACB (i.e. would not have been eligible for LORIS for several 
reasons). Long-term outcome data from these series show that 
while a substantial number subsequently developed invasive 
tumours these occurred over a very long timescale [12-15]. It was 
considered appropriate in this first trial of active monitoring to 
mandate at least 10 years of annual mammograms. Even longer 
follow-up is probably needed to produce data regarding the impact 
on mortality and we have recognised the need to attract future 
funding for life long follow up in LORIS.  
 
Recall and investigation.  
While spontaneous regression of DCIS has been proposed by some, 
it is assumed that the diagnosis of DCIs in these patients will persist 
long term and the object of follow up is to detect and treat 
subsequent invasive disease.  An increase in the number, or size, of 
the microcalcification in the index lesion will  not prompt routine 
patient recall, neither will changes in the appearances/morphology, 
as casting type microcalcification is known to become more 
prevalent with increasing  size.    
Mammographic changes that trigger protocol recall for further 
investigations are as follows: 
 A new cluster of microcalcification which is not definitively 
benign, outwith the index lesion/quadrant or remote from the 
index lesion; 
 A new cluster of microcalcification, which is not definitively 
benign, in the contralateral breast; 
 A new non-calcified lesion, which is not definitively benign, in 
either breast; 
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 Developing asymmetry or mass around the index calcification.  
 
 
A second opinion service for participating radiologists is 
incorporated in the trial to promote a uniform approach in equivocal 
situations. 
 
Recall in the surgical arm will be performed in line with standard 
practice.   
 
IMAGING  TISSUE BANKS AND TRANSLATIONAL RESEARCH 
Both the tissue samples and radiological imaging are being banked 
prospectively for future translational research. There have been 
multiple challenges that act as barriers to effective and high quality 
translational research in DCIS. These include some local variations 
in assessment of pathology, receipt of small samples, the 
requirement for fixation of all tissue for accurate diagnosis, 
incomplete follow up, low event rates, and lack of distinction 
between invasive versus DCIS recurrence in some of the published 
literature. Each of these, individually, restricts progress in this field. 
Within the LORIS trial, we are presented with a unique opportunity 
to surmount each of these obstacles, when linked to advances in 
current technology that allow the analysis of gene expression from 
very small quantities of DNA/RNA (100-200ng) or from 
microdissected samples of as few as 100-1000 cells. 
 
A widely recognised high priority breast cancer research question is 
to determine the factors in DCIS lead to progression into invasive 
carcinoma [16]. There is limited information on the functional 
molecular events that drive progression of DCIS from the primary 
diagnosis of a pure in situ carcinoma to a frankly invasive lesion. It 
remains challenging to build a comprehensive picture of the events 
involved in progression of pure DCIS to invasive cancer with any 
certainty. Complex, branched models are proposed, with multiple 
mutational events driving multiple routes to invasive cancer [17-
19], however recent data suggests that at least some fraction of 
pure DCIS may be molecularly distinct from DCIS which is identified 
associated with invasive cancer [20, 21]. It may be that some DCIS 
may not develop the molecular alterations which lead to invasive 
cancer and therefore may represent a molecular state with low risk 
of progression.  
 
Whilst there are several potential diagnostic profiles available for 
risk stratification following a diagnosis of DCIS, existing candidate 
approaches, such as the Genomic Health “DCIS Score” [22] or the 
Kerlikowske triple positive IHC profile [23] have been unvalidated, 
until a recent report at San Antonio (2014) indicating a utility to the 
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“DCIS Score” [24]. The LORIS trial will prospectively collect 
diagnostic samples and immediate resection samples from those 
women undergoing surgery, as well as tissue samples from re-
biopsy events and delayed surgical resections when these are 
required.  This will form an annotated tissue sample collection to 
validate existing, and identify novel, molecular profiles associated 
with both indolence and progression to invasive disease.   
 
An Imaging Data Repository is a further valuable resource in LORIS. 
There is minimal information on how microcalcification, managed 
without surgery, changes over time and what, if any, signs precede 
progression to invasive disease. It is planned to prospectively bank 
all radiological images from the active monitoring arm. 
 
STATISTICAL DESIGN AND END POINTS 
As surgery is currently the standard of care, a non-inferiority design 
was considered most appropriate to answer the primary research 
question: is active monitoring non-inferior to surgery in terms of 
ipsilateral invasive breast cancer survival? The primary analysis will 
be a comparison of the ipsilateral invasive disease free survival time 
between the active monitoring and surgery arms using a log-rank 
test for non-inferiority on a per protocol and intent to treat 
population. The one-sided type I error is set at 5% and power is 
80% and assumes a 5 year ipsilateral loco-regional disease free 
survival rate of 97.5% in the surgery arm. To exclude a difference 
of more than 2.5% at 5 years requires 932 patients (allowing for a 
10% loss to follow-up). 
 
This trial will generate a wealth of additional data has multiple 
prospectively planned secondary endpoints, as summarised in table 
2. 
 
 
PATIENT REPORTED OUTCOME MEASURURES 
Patient reported outcomes are of particular interest in this trial and 
will provide valuable data on the reasons why women choose to 
take part, or not, and the anxiety related to being actively 
monitored or, conversely, undergoing surgery. These data will 
inform other trials of active monitoring that are likely to follow. 
Whatever the patient reported outcomes, future generations of 
women diagnosed with low risk DCIS will be in a position to make 
informed choices, which are not currently possible. The primary 
quality of life aspect of the trial examines the hypothesis that the 
psychological well-being of women in the Active Monitoring arm is 
non-inferior to that associated with standard surgical and adjuvant 
treatments. Patients will be asked to complete questionnaires at 
different time points that will look at factors that may influence: 
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 Decision to join, or reject, the trial using the Accept/Decline 
questionnaire 
 Psychological adjustment - anxiety trait and ways of coping. 
Using the Speilberger State-Trait Anxiety Inventory (STAI) and 
Brief ways of coping questionnaire  
In addition, the impact that surgery and active monitoring may 
have on anxiety state and general well-being is measured using 
STAI and SF-36v2 Health Survey. 
 
HEALTH ECONOMICS 
If active monitoring is found to be an effective approach in the 
treatment for centrally confirmed low risk DCIS, then it is likely that 
there will be important cost implications for the health care sector. 
For example, the patient will avoid initial standard surgery and 
adjuvant treatment and will instead be monitored by annual 
mammography and be treated as an outpatient, thus avoiding an 
inpatient stay, and resources may potentially be saved. However, 
active monitoring may, or may not, incur unexpected or 
unscheduled costs due to additional appointments for reassurance 
using health care resources, for example in providing counselling 
between mammography screens. Therefore all associated resource 
use costs incurred by both approaches need to be assessed in 
conjunction with measures of effectiveness.  
 
The aim of the economic evaluation is to determine the cost-
effectiveness of active monitoring compared with surgery and 
adjuvant therapy for low risk DCIS. Although the trial has been 
designed as a non-inferiority trial, the most appropriate type of 
analysis is a cost-effectiveness analysis [25]. Cost-effectiveness will 
be determined in two ways: a cost-effectiveness analysis will be 
undertaken based on a number of outcomes, including the cost per 
additional surgical treatment avoided at 10 years and cost per 
diagnosis of ipsilateral breast cancer, utilising the clinical outcome 
data collected within the trial. In addition, a cost-utility analysis will 
be undertaken to calculate the cost per additional quality-adjusted 
life year (QALY) gained. The utility values required to calculate 
QALYs will be obtained by administering the EuroQol EQ-5D 
questionnaire at various time points. In the first instance, the 
evaluation will consider costs incurred by the health service in the 
delivery of both treatment pathways. However, information on costs 
incurred by patients will also be collected in order that an evaluation 
from a wider societal perspective can also be undertaken. 
 
RECRUITMENT 
The SHORE-C team at the University of Sussex held in-depth 
patient focus groups to explore and demonstrate widespread 
acceptability of the LORIS trial concept [26]. The lessons learned 
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from the PROTECT trial of observation versus immediate treatment 
for screen detected prostate cancer have been heeded [27, 28]. For 
example, women are informed about the trial before they receive 
their diagnosis of DCIS and a DVD is used to provide an even-
handed approach to introducing the trial. The language used in the 
patient information literature and DVD has been carefully worded 
and, in keeping with contemporary opinion, does not utilise the 
word “carcinoma” as part of the description of DCIS [29]. 
 
TRIAL PROGRESS 
The trial opened to recruitment in July 2014 and has an in-built 
feasibility study in which 20 sites will be opened to recruitment in 
the first instance. Sixty randomized patients are required within 2 
years of opening before further sites can join the trial. This tests the 
ability to open sites in a timely fashion, assesses clinicians’ and 
womens’ agreement to take part, and ensures that adherence to 
the randomized arm are all sufficient to accrue the full sample size 
in a timely fashion.  
 
The main challenges so far have been slow site set-up (eleven sites 
are now open at six months; the mean time for setting up sites in 
the UK in 2014 is 9.7 months [30]) and the reluctance of NHS 
Trusts to fund first line VACBs, despite much published evidence 
that they are the gold-standard for evaluation of microcalcifications 
and have a better concordance with excision histology than small 
volume cores [10, 11]. 
 
The unique central histopathology review process is working well; 
the one week turnaround for review is being achieved by the expert 
pathology reviewers (2 of whom are required for each case 
reviewed, with the third to provide arbitration).  
 
We have encountered a remarkable enthusiasm from our open sites 
with a clear determination by the multi-disciplinary teams to make 
this trial a success. As of December 2014, the trial has reached its 
milestones for site opening, patients registered and patients 
randomised. 
 
Looking beyond DCIS it is notable that some screen detected 
invasive cancers, notably tubular carcinomas, are associated with a 
very indolent course, rarely result in distant metastasis and carry 
excellent prognosis [31]. These, and similar cancers, represent a 
further context in which overtreatment is likely. Additional 
minimisation of overtreatment will require us to address the 
alternative management of indolent screen detected invasive cancer 
and is the focus of active discussion within our group.  
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